OPEN ACCESS

Inter-individual variation in midazolam clearance in children

Mohammed I Altamimi, Helen Sammons, Imti Choonara

Academic Division of Child Health, University of Nottingham, Derbyshire Children's Hospital, Derby, UK

Correspondence to Mohammed I Altamimi, Academic Division of Child Health, University of Nottingham, Derbyshire Children's Hospital, Derby DE22 3DT, UK; mxma2@nottingham.ac.uk

Received 22 November 2013
Revised 9 September 2014
Accepted 10 September 2014
Published Online First 3 October 2014

ABSTRACT

Objectives To determine the extent of inter-individual variation in clearance of midazolam in children and establish which factors are responsible for this variation.

Methods A systematic literature review was performed to identify papers describing the clearance of midazolam in children. The following databases were searched: Medline, Embase, International Pharmaceutical Abstracts, CINAHL and Cochrane Library. From the papers, the range in plasma clearance and the coefficient of variation (CV) in plasma clearance were determined.

Results 25 articles were identified. Only 13 studies gave the full range of clearance values for individual patients. The CV was greater in critically ill patients (18%–170%) than non-critically ill patients (13%–54%). Inter-individual variation was a major problem in all age groups of critically ill patients. The CV was 72%–106% in preterm neonates, 18%–73% in term neonates, 31%–130% in infants, 21%–170% in children and 47%–150% in adolescents. The mean clearance was higher in children (1.1–16.7 mL/min/kg) than in neonates (0.78–2.5 mL/min/kg).

Conclusions Large inter-individual variation was seen in midazolam clearance values in critically ill neonates, infants, children and adolescents.

INTRODUCTION

Midazolam is a short acting benzodiazepine that is used in the treatment of prolonged seizures and as a sedative for both procedures and critically ill children who are ventilated.¹ In critically ill children, it is administered by the intravenous route as an infusion. For procedures, it is often administered orally. After oral administration, it is absorbed rapidly from the gastrointestinal tract and the maximum plasma concentration is achieved within 30 min.

Dosing of midazolam, like most medicines used in children, is based on body weight.^{2–4} Dosing in children is usually extrapolated from pharmacokinetic studies in adults. These are initially performed on healthy adult volunteers. Before a medicine is used in children, there is usually significant clinical experience in adults, alongside scientific studies including pharmacokinetic studies in adult patients receiving the medication. These are adults with different illnesses who may handle the drug differently to healthy adult volunteers. Pharmacokinetic studies in children receiving midazolam are of benefit in ensuring that appropriate doses are given. However, doses are usually calculated from mean pharmacokinetic values. It is important to be aware that there is often significant inter-individual variation in the pharmacokinetics, and in particular the clearance of a medicine, due to factors such as

What is already known on this topic

- ▶ Midazolam clearance varies with age.
- ▶ Critical illness is a major determinant of clearance.

What this study adds

- ▶ There is a large inter-individual variation in midazolam clearance in critically ill children and neonates.
- ▶ It is likely that many critically ill children are either underdosed or overdosed with midazolam.

age,⁵ weight,⁶ disease⁷ and ethnicity/genotype.⁸ Recently, other more specific methods such as population pharmacokinetics (PK) modelling have been developed. This allows for age appropriate individualisation of dosing for children.⁹

We wished to explore which factors were associated with the greatest inter-individual variation in midazolam clearance in paediatric patients. We therefore performed a systematic review of pharmacokinetic studies in paediatric patients involving midazolam.

METHODS

A systematic literature search was performed to identify all papers describing the clearance of midazolam in children. The following databases were used: MEDLINE (1946 to May 2012), EMBASE (1974 to May 2012), International Pharmaceutical Abstracts (1970 to April 2012), CINAHL and Cochrane Library. The databases were searched separately and combined together to remove duplications. The search strategy included all languages and involved the keywords: 'midazolam' AND 'child*' OR 'p*ediatric*' OR 'infant*' OR 'new-born*' OR 'neonate*' OR 'adolescent*' AND 'pharmacokinetic*' OR 'clearance' OR 'half-life' OR 'absorption' OR 'distribution' OR 'metabolism' OR 'elimination' OR 'pharmacodynamic*'.¹⁰

We excluded the following: review articles, editorials, conference abstracts, studies in adults aged 18 years and over, and studies that involved adults and paediatric patients where the paediatric data were not presented separately. Studies in which midazolam was not administered intravenously were also excluded as clearance is dependent on

Open Access
Scan to access more
free content

CrossMark

To cite: Altamimi MI, Sammons H, Choonara I. *Arch Dis Child* 2015;**100**:95–100.

bioavailability if administered orally or rectally. Inclusion criteria were original research studies assessing the pharmacokinetics of midazolam in children up to the age of 18 years. Data such as number of patients, ethnicity, dose and clearance were extracted. The mean/median clearance as well as both the minimum and maximum clearance values was noted. The variation ratio was calculated from the range of clearance (maximum clearance divided by the minimum clearance). The coefficient of variation (CV) was extracted from the paper if given. If individual data were presented, then the CV was calculated using the formula $CV = \sqrt{((e^{SD^2}) - 1)}$ which allows for the fact that clearance is usually log normally distributed in children. If individual data were not available, then CV was estimated by dividing the SD by the mean of clearance, i.e., normal distribution assumed. Patients were divided into two groups: (1) critically ill if they were in an intensive care unit and (2) non-critically ill which included other groups. We also contacted original authors by email if their paper did not give the full range of clearance values but only gave mean clearance values.

RESULTS

A total of 1654 articles were identified but only 25 articles met the inclusion criteria^{7 11–34} (figure 1). The 1367 articles that were excluded were 613 studies where data for midazolam were not presented, 359 studies that did not give data for midazolam pharmacokinetics, 245 review articles, 122 studies in adults, 16 conference abstracts, eight editorials, and one study involving adults and paediatric patients where the paediatric data were not presented separately. Three studies that involved oral/rectal administration of midazolam were excluded. Two authors provided individual data in response to the email request and this has been included in the table. Fourteen studies stated the compartment model used for the PK analysis. Seven used a two compartment model,^{11 12 14 15 17 18 21} one used a three compartment model,³¹ one used both one and two compartment model¹⁷ and five used a non-compartment model.^{13 16 24 25 28} Ethnicity was described in only four studies.^{15 16 24 30} All studies except two were population PK studies. Six papers stated the CV.^{14 15 17–19 21} Six other papers provided individual data allowing calculation of CV.^{12 16 20 22 29 31} In nine papers, only

Figure 1 Flow chart of the search performed.

Figure 2 Range of coefficient of variation for different patient groups.

the SD was reported and therefore CV was estimated assuming normal distribution.^{11 20 25–28 30 33 34} The CV for all paediatric age groups ranged between 13% and 170% (figure 2).

Nine studies reported midazolam clearance in 349 critically ill neonates undergoing sedation for mechanical ventilation (table 1). The CV in four studies in preterm neonates ranged from 72% to 106%. The CV in four studies in term neonates ranged from 18% to 73%. Four studies gave the full range of clearance values for individual neonates.^{11–13 16} Three studies in preterm neonates suggested a 4.5-, 5- and 10-fold variation in clearance in 15, 10 and 24 neonates, respectively.^{11–13} One study involving five term neonates reported a twofold variation in clearance.¹⁶ The mean clearance in preterm neonates ranged from 0.78 to 2.1 mL/kg/min and in term neonates ranged from 1.17 to 2.5 mL/kg/min.

Four studies reported midazolam clearance in critically ill infants.^{16 20–22} The CV ranged from 31% to 130%. The CV was lowest in the study where the infants were not ventilated.²¹ All four studies gave the full range of clearance values for individual infants. There was a 6–43-fold variation in clearance values.

Five studies reported clearance values in critically ill children.^{16 20 23–25} The CV ranged from 21% to 170%. Four studies gave the full range of clearance values for individual children. There was a twofold to fivefold variation in clearance values in three studies and a 133-fold variation in one study.^{16 20 23 24}

Two small studies in critically ill adolescents had a CV of 47% and 150%. There was a 2.5–5-fold variation in clearance values.

Three other studies in critically ill children included data from neonates and did not present the data in relation to age (table 1). The CV was 78% in both of these studies. There was a 29–32-fold variation in clearance values.

The studies in critically ill neonates, infants, children and adolescents all documented significant inter-individual variation in clearance. One study where the authors provided individual data excluded data from three patients where there was even greater inter-individual variation due to their renal failure, hepatic failure and concomitant erythromycin-fentanyl therapy.¹⁶

There were seven studies that reported midazolam clearance in non-critically ill infants, children and adolescents (table 2). The CV ranged from 13% to 54%. Four of these studies gave

the full range of clearance values for individual patients.^{29–32} The degree of inter-individual variation in clearance in these children ranged from 2-fold up to 10.5-fold.

The mean clearance was highest in children and lowest in preterm neonates. The CV was greater in critically ill patients of all ages than non-critically ill (table 3).

DISCUSSION

Inter-individual variation in midazolam clearance was greater in critically ill patients than non-critically ill patients. The CV was greater than 50% in the majority of studies in critically ill patients. Midazolam is administered by a continuous intravenous infusion in critically ill children and the dose is titrated in relation to the response. There is a fourfold variation in dosage administration (30–120 µg/kg/h) for children between the ages of 6 months and 12 years.³ There was, however, a greater than fourfold variation in midazolam clearance in the majority of studies in the critically ill. The greater variation in midazolam clearance values than the dosage schedule suggests that many children may receive too high or too low a dose of midazolam in order to obtain satisfactory sedation. This may explain the poor sedation achieved in clinical trials with midazolam in critically ill children.³⁵

Critical illness may extensively affect midazolam clearance in both children³⁶ and adults.^{37 38} Three studies in critically ill adults suggested a 12–20-fold variation in midazolam clearance with variation in dose between 2- and 10-fold.^{37–39} One of the first studies of midazolam in critically ill children described a 40-fold variation in plasma concentrations of midazolam despite there being only a 2.5-fold variation in dosage.⁴⁰ Several factors can affect the pharmacokinetics of drugs in critically ill patients.⁴¹ Both hypoxia and shock are common in the critically ill. The liver is sensitive to hypoxia as the majority of its blood supply is from the portal vein where blood has a low oxygen content.⁴¹ Hypoxia can affect the cells in the liver which are responsible for blood metabolism. Shock which is common in critically ill patients, especially prior to admission to an intensive care unit, results in a reduced blood flow to the liver, which results in a reduction in enzyme activity in hepatocytes. The clearance of morphine was reduced in adults with shock following acute trauma.⁴² Other factors that can affect drug metabolism in the critically ill include systemic inflammatory responses.⁴¹ Inflammatory mediators such as interleukin 1, interleukin 6, tumour necrosis factors and interferon may all have an effect on drug metabolism.⁴³ Stress, changes in diet, endocrine changes and other drugs may also affect drug metabolism.⁴¹ Mechanical ventilation can reduce cardiac output and therefore reduce blood flow to the organs, especially the liver and kidneys, which are responsible for drug clearance.⁴⁴ However, reduced blood flow to the liver does not substantially affect midazolam clearance as it is not a high extraction ratio drug. Changes in volume of distribution can occur as a result of infection and inflammation in critically ill patients. Endotoxins from infective agents can affect the endothelium of blood vessels, causing either vasoconstriction or vasodilatation which can lead to abnormal distribution of drugs.⁴¹

There was significant inter-individual variation in critically ill neonates with a 2–10-fold variation in plasma clearance values and CV between 18% and 106%. Midazolam is administered by continuous intravenous infusion in critically ill neonates and the dose titrated according to the response. However, there is no 10-fold variation in doses used in neonates. In the papers listed in this review, there was a fourfold variation in midazolam dosage in neonates. The CV was greater in preterm neonates

Table 1 Midazolam clearance in critically ill paediatric patients

Age group	Number of patients	Range of weight (kg)	Mean clearance (mL/kg/min)	SD	Coefficient of variation (CV) (%)	Range of clearance (mL/kg/min)	Variation ratio in clearance	Comments	Study
Preterm neonates	15	1–3.3	1.7	1.8	106	0.6–2.7	4.5	–	Jacqz-Aigrain <i>et al</i> ¹¹
	10	2.3–3.9	2.1	1.3	72	0.7–3.7	5	Individual data available	Jacqz-Aigrain <i>et al</i> ¹²
	24	0.8–1.6	1.8*	NA	NA	0.7–6.7	10	–	de Wildt <i>et al</i> ¹³
	9	0.7–1.4	1.7	1.4	81	NA	NA	CV provided by authors	Harte <i>et al</i> ¹⁴
	33	0.5–1	0.78	0.6	83	NA	NA	The only population PK study with omega ² /eta values	Lee <i>et al</i> ¹⁵
	27	1–1.65	1.24	0.9	78	NA	NA	CV provided by authors	
Term neonates	5	2.8–3.8	2.5	0.75	30	1.8–3.7	2	Two stage PK study	de Wildt <i>et al</i> ¹⁶
	187	0.7–5.2	1.17<39/40 GA 1.84>39/40 GA	0.7 1.2	65	NA	NA	Individual data available CV provided by authors	Burtin <i>et al</i> ¹⁷
	20	2.7–3.9	2.6	NA	18	NA	NA	Pre-ECMO CV provided by authors	Ahsman <i>et al</i> ¹⁸
	19	3.4†	1.4	1	73	NA	NA	Post-ECMO CV provided by authors	Mulla <i>et al</i> ¹⁹
>28 days–23 months	25	NA	6	7	130	0.6–25.8	43	Individual data available	Hughes <i>et al</i> ²⁰
	6	3.6–20	4.8	5	89	1.8–16	9	Two stage PK study	de Wildt <i>et al</i> ¹⁶
	24	5.1–12	16.7	5.2	31	0.1–0.6	6	Individual data available Not ventilated, mL/min (not kg ⁻¹)	Peeters <i>et al</i> ²¹
	2	NA	2	1.8	50	0.4–3	7.5	CV provided by authors Two stage PK study	Minagawa and Watanabe ²²
								Individual data available	
2–11 years	5	13–88	1.1	NA	NA	0.9–3.8	4	–	Roberts <i>et al</i> ²³
	4	15–40	6	3.8	72	2.3–11	5	Two stage PK study	de Wildt <i>et al</i> ¹⁶
	12	8.7–12	14.4	NA	NA	9.2–19.7	2	Individual data available	Muchohi <i>et al</i> ²⁴
	12	NA	15.5	20	170	0.5–66.6	133	–	Hughes <i>et al</i> ²⁰
	6	6.4–25	12	6.6	55	NA	NA	Individual data available	Mathews <i>et al</i> ²⁵
	6		8.5	1.8	21	NA	NA	–	
	5		9.1	3.4	37	NA	NA	–	
								–	
12–18 years	3	50–62	3.2	1.6	47	2–5	2.5	–	de Wildt <i>et al</i> ¹⁶
	3	NA	5	4.5	150	1.5–8	5	Two stage PK study Individual data available	Minagawa ²²
2 days–17 years	21	3.8–24.5	5	3.9	78	NA	NA	–	Vet <i>et al</i> ²⁶
8 days–16.2 years	22	NA	NA	NA	NA	1.6–51.6	32	–	Nahara <i>et al</i> ⁷
26 days–5 years	24	NA	13.5	10.6	78	1.5–43.4	29	–	Hartwig <i>et al</i> ²⁷

*Median.

†Mean.

CV, coefficient of variation; ECMO, extracorporeal membrane oxygenation; GA, gestational age; NA, not available.

Table 2 Midazolam clearance in non-critically ill children

Age group	Number of patients	Range of weight (kg)	Mean clearance (mL/kg/min)	SD	Coefficient of variation (%)	Range of clearance (mL/kg/min)	Variation ratio in clearance	Type of patients	Comments	Study
>28 days–23 months	5	2.8–12.8	11.3	6	53	NA	NA	Minor surgery	Two stage PK study	Reed <i>et al</i> ²⁸
2–11 years	6	11–17	13.3	4	41	9.5–17.8	2	Minor surgery	Individual data available	Rey <i>et al</i> ²⁹
	12	14–38.5	15.3	3.1	20	11–23	2	Minor surgery	–	Jones <i>et al</i> ³⁰
	6	22–30	3.2	1.1	54	1.1–6.5	6	Minor surgery	Individual data available	Kraus <i>et al</i> ³¹
	21	23.2*	NA	NA	NA	1.3–13.7	10.5	Elective surgery	–	Salonen <i>et al</i> ³²
	14	19.5*	10	3.8	38	NA	NA	Minor surgery	Two stage PK study	Reed <i>et al</i> ²⁸
	8	8.4–26.2	9.1	1.2	13	NA	NA	Minor surgery	–	Payne <i>et al</i> ³³
12–18 years	20	NA	10	5	50	NA	NA	Endoscopy	–	Tolia <i>et al</i> ³⁴
	2	62*	9.3	3.8	40	NA	NA	Minor surgery	Two stage PK study	Reed <i>et al</i> ²⁸

*Mean.
NA, not available.

(72%–106%) than term neonates (18%–73%). Clearance is lower in neonates than older children and adolescents due to the immaturity of drug metabolism process in neonates.

The major pathway of midazolam metabolism is oxidation, which involves the cytochrome P450 (CYP) dependent enzymes. The major CYP enzymes are CYP3A4, CYP3A5 and CYP3A7. CYP3A4 activity is significantly reduced in neonates. CYP3A7 has the greatest activity in the neonatal period, but does not contribute substantially to metabolism.⁴⁵ There is, however, less inter-individual variation in CYP3A7 mRNA in fetal liver than variations in CYP3A4 levels found in adult liver.⁴⁶ CYP3A4 levels increase progressively from about a tenth of adult levels in preterm neonates to approximately adult levels at 6 months.

Inter-individual variation in midazolam clearance was lower in non-critically ill children. The CV was however still large (13%–54%) with a 2–10-fold variation in plasma clearance values. This suggests that even non-critically ill children may be overdosed or underdosed. A recent study developed a model-based approach to individualise midazolam dose based on in vivo maturation function for CYP3A mediated clearance from birth to adulthood.⁴⁷ Model-based approaches are a welcome addition to ensuring paediatric patients receive the correct dose. However, models do not eliminate inter-individual variation. One therefore needs to titrate the dose.

The role of genetic polymorphism of CYP3A in inter-individual variation of drug disposition has been studied previously. This review could not distinguish any differences in variability between different ethnic subpopulations as the majority of the studies did not document the ethnicity of the sample patients.

In conclusion, this systematic review has identified that inter-individual variation in midazolam clearance is greatest in critically ill children and neonates. The degree of inter-individual variation in critically ill paediatric patients is far greater than the variation in doses administered. This suggests that some patients may receive inadequate doses while others receive excessive doses. Assessment of the response to midazolam in these clinical situations is therefore essential with recognition that higher doses may be needed to achieve adequate sedation. More research is also needed to establish the safety of higher dose ranges.

Acknowledgements We would like to thank Dr Saskia De Wildt and Professor John van den Anker for providing individual data for their patients.

Contributors MIA, HS and IC conceived the idea as part of MIA's PhD. MIA did the literature search and extracted the data. HS and IC reviewed and validated the extracted data. MIA wrote the first draft and IC edited the draft and subsequent drafts. MIA, HS and IC agreed to the final draft.

Funding None.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- Blumer JL. Clinical pharmacology of midazolam in infants and children. *Clin Pharmacokinet* 1998;35:37–47.
- Baber N, Pritchard D. Dose estimation for children. *Br J Clin Pharmacol* 2003;46:489–93.
- Paediatric Formulary Committee. *BNF for children*. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications, 2013–2014:638–39.
- Anderson BJ, Holford NH. Understanding dosing: children are small adults, neonates are immature children. *Arch Dis Child* 2013;98:737–44.
- De Gast-Bakker DA, van der Werff SD, Sibarani-Ponsen R, *et al*. Age is of influence on midazolam requirements in a paediatric intensive care unit. *Acta Paediatr* 2007;96:414–17.
- Maitre PO, Buhrer M, Thomson D, *et al*. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. *J Pharmacokinet Biopharm* 1991;19:377–84.
- Nahara M, McMorrow J, Jones P, *et al*. Pharmacokinetics of midazolam in critically ill paediatric patients. *Eur J Drug Metab Pharmacokinet* 2000;25:219–21.

Table 3 Coefficient of variation for midazolam clearance in paediatrics

Age	Critically ill (%) (n)	Non-critically ill (%) (n)
Preterm neonates	72–106 (118)	–
Term neonates	18–73 (231)	–
Infants	31–130 (57)	53 (5)
children	21–170 (50)	13–54 (67)
Adolescents	47–150 (6)	40–50 (22)

- 8 Guo T, Mao GF, Xia DY, *et al.* Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. *J Clin Pharm Ther* 2011;36:406–11.
- 9 Admiraal R, van Kesteren C, Boelens JJ, *et al.* Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. *Arc Dis Child* 2014;99:267–72.
- 10 Kastner M, Wilczynski NL, Walker-Dilks C, *et al.* Age-specific search strategies for Medline. *J Med Internet Res* 2006;8:25.
- 11 Jacqz-Aigrain E, Daoud P, Burtin P, *et al.* Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. *Eur J Clin Pharmacol* 1992;42:329–32.
- 12 Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. *Eur J Clin Pharmacol* 1990;39:191–2.
- 13 De Wildt SN, Kearns GL, Hop WC, *et al.* Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. *Clin Pharmacol Ther* 2001;70:525–31.
- 14 Harte GJ, Gray PH, Lee TC, *et al.* Haemodynamic responses and population pharmacokinetics of midazolam following administration to ventilated, preterm neonates. *J Paediatr Child Health* 1997;33:335–8.
- 15 Lee TC, Charles BG, Harte GJ, *et al.* Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. *Anesthesiology* 1999;90:451–7.
- 16 De Wildt SN, de Hoog M, Vinks AA, *et al.* Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. *Crit Care Med* 2003;31:1952–8.
- 17 Burtin P, Jacqz-Aigrain E, Girard P, *et al.* Population pharmacokinetics of midazolam in neonates. *Clin Pharmacol Ther* 1994;56:615–25.
- 18 Ahsman MJ, Hanekamp M, Wildschut ED, *et al.* Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. *Clin Pharmacokinet* 2010;49:407–19.
- 19 Mulla H, McCormack P, Lawson G, *et al.* Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. *Anesthesiology* 2003;99:275–82.
- 20 Hughes J, Gill AM, Choonara I, *et al.* Steady-state plasma concentrations of midazolam in critically ill infants and children. *Ann Pharmacother* 1996;30:27–30.
- 21 Peeters MY, Prins SA, Knibbe CA, *et al.* Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. *Anesthesiology* 2006;105:1135–46.
- 22 Minagawa K, Watanabe T. [A pharmacokinetic study of midazolam for the treatment of status epilepticus in children: a preliminary report]. *No To Hattatsu* 2006;38:301–3.
- 23 Roberts JA, Coulthard MG, Addison RS, *et al.* Midazolam metabolism: implications for individualized dosing? *J Pharm Pract Res* 2009;39:198–201.
- 24 Muchohi SN, Kokwaro GO, Ogutu BR, *et al.* Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. *Br J Clin Pharmacol* 2008;66:529–38.
- 25 Mathews HM, Carson IW, Lyons SM, *et al.* A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. *Br J Anaesth* 1988;61:302–7.
- 26 Vet NJ, de Hoog M, Tibboel D, *et al.* The effect of critical illness and inflammation on midazolam therapy in children. *Pediatr Crit Care Med* 2012;13:48–50.
- 27 Hartwig S, Roth B, Theisohn M. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. *Eur J Pediatr* 1991;150:784–8.
- 28 Reed MD, Rodarte A, Blumer JL, *et al.* The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. *J Clin Pharmacol* 2001;41:1359–69.
- 29 Rey E, Delaunay L, Pons G, *et al.* Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. *Eur J Clin Pharmacol* 1991;41:355–7.
- 30 Jones RD, Chan K, Roulson CJ, *et al.* Pharmacokinetics of flumazenil and midazolam. *Br J Anaesth* 1993;70:286–92.
- 31 Kraus GB, Gruber RG, Knoll R, *et al.* [Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. *Anaesthesist* 1989;38:658–63.
- 32 Salonen M, Kanto J, Iisalo E, *et al.* Midazolam as an induction agent in children: a pharmacokinetic and clinical study. *Anesth Analg* 1987;66:625–8.
- 33 Payne K, Mattheyse FJ, Liebenberg D, *et al.* The pharmacokinetics of midazolam in paediatric patients. *Eur J Clin Pharmacol* 1989;37:267–72.
- 34 Tolia V, Brennan S, Aravind MK, *et al.* Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. *J Pediatr* 1991;119:467–71.
- 35 Parkinson I, Hughes J, Choonara I, *et al.* A randomized controlled trial of sedation in the critically ill. *JAMA* 1997;277:405–10.
- 36 Ince I, de Wildt SN, Peeters MYM, *et al.* Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. *Ther Drug Monit* 2012;34:381–9.
- 37 Shafer A, van Doze A, White PF, *et al.* Pharmacokinetic variability of midazolam infusions in critically ill patients. *Crit Care Med* 1990;18:1039–41.
- 38 Kinoshita K, Sakurai A, Mera K, *et al.* Midazolam for continuous sedation in Japanese critical care patients: Phase II study. *J Int Med Res* 2001;29:342–8.
- 39 Oldenhof H, de Jong M, Steenhoek A, *et al.* Clinical Pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? *Clin Pharmacol Ther* 1988;43:263–9.
- 40 Lloyd-Thomas AR, Booker PD. Infusion of midazolam in paediatric patients after cardiac surgery. *Br J Anaesth* 1986;58:1109–15.
- 41 Park GR. Molecular mechanisms of drug metabolism in the critically ill. *Br J Anaesth* 1996;77:32–49.
- 42 Christie J, Markowsky SJ, Valdes C. Acute trauma alters morphine clearance. *J Trauma* 1995;39:749–52.
- 43 Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. *Clin Pharmacol Ther* 2009;85:434–8.
- 44 Richard C, Berdeaux A, Delion F, *et al.* Effect of mechanical ventilation on hepatic drug pharmacokinetics. *Chest* 1966;90:837–41.
- 45 Williams JA, Ring BJ, Cantrell VE, *et al.* Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. *Drug Metab Dispos* 2002;30:883–91.
- 46 DeWildt SN, Kearns GL, Leeder JS, *et al.* Cytochrome P450 3A: ontogeny and drug disposition. *Clin Pharmacokinet* 1999;37:485–505.
- 47 Ince I, de Wildt SN, Wang C, *et al.* A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. *Clin Pharmacokinet* 2013;52:555–65.